Stocks · Korea
331920
KOSDAQ
Celemics
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-07 basis
Returns and 52-week range
1W+0.09%
1M-25.94%
3M-7.75%
6M-19.95%
1Y+238.88%
YTD+289.34%
52W high19,840원
52W low2,535원
From 52W high-46.62%
Financial results (consolidated)
| Period | Revenue | Operating income | Net income | OP margin |
|---|---|---|---|---|
| 2023 | 66억 | -58억 | -39억 | -87.7% |
| 2024 | 67억 | -19억 | 123억 | -28.3% |
| 2025 | 58억 | -33억 | -40억 | -57.6% |
| Quarterly | ||||
| 2024 4Q | 20억 | -1억 | -93억 | -7.0% |
| 2025 1Q | 17억 | -4억 | -22억 | -25.9% |
| 2025 2Q | 11억 | -13억 | -29억 | -119.5% |
| 2025 3Q | 13억 | -11억 | -15억 | -85.4% |
| 2025 4Q | 17억 | -5억 | 26억 | -27.5% |
| 2026 1Q | 9억 | -14억 | -60억 | -154.4% |
Company
Address: 서울특별시 금천구 가산디지털1로 131, A동 19층 및 20층 2004호 외  
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| 한독 | 1,191억 | — | 0.41 | -9.66% |
| 옵투스제약 | 1,133억 | 8.78 | 0.65 | +10.88% |
| 코아스템켐온 | 1,245억 | — | 2.05 | +7.78% |
| 프레스티지바이오로직스 | 1,093억 | — | 0.81 | -19.79% |
| 동성제약 | 1,249억 | — | 1.35 | -8.82% |
| 하이텍팜 | 1,070억 | 9.32 | 0.82 | -0.29% |
Recent filings
- 2026-09-14[기재정정]주요사항보고서(유상증자결정) Major
- 2026-08-14반기보고서 (2026.06)
- 2026-06-24[기재정정]주요사항보고서(유상증자결정) Major
- 2026-06-24주요사항보고서(유상증자결정) Major
- 2026-06-23[기재정정]주요사항보고서(유상증자결정) Major
- 2026-05-21[기재정정]주요사항보고서(유상증자결정) Major
- 2026-05-15분기보고서 (2026.03)
- 2026-05-12[기재정정]주요사항보고서(유상증자결정) Major
- 2026-04-29[기재정정]주요사항보고서(전환사채권발행결정) Major
- 2026-04-22[기재정정]주요사항보고서(유상증자결정) Major
Source: DART (Financial Supervisory Service electronic disclosure)
Recent news
- 2026-09-04"3년 최소 99억 확보" 셀레믹스, 美 '암 진단' 대형 계약…배경은... 머니투데이
- 2026-06-24셀레믹스, 100억원 규모 제3자배정 유상증자 결정 이데일리
- 2026-05-20바이오 기업 셀레믹스 투자한 수앤파이낸셜, 경영권 인수 가능성도 조선비즈
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.